Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 10/20 | 0.62 |
| ▸ | CPT2 | P23786 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | CPT1B | Q92523 | 8/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL754059 | 0.91 | CPT1A (0.67) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL752542 | 0.90 | CPT1A (0.60) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL752531 | 0.90 | CPT1A (0.77) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL752496 | 0.89 | CPT1A (0.59) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL753485 | 0.87 | CPT1A (0.68) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL755026 | 0.87 | CPT1A (0.80) | CPT1ACPT2MAPTSMN1; SMN2USP2 | |
| SCHEMBL752161 | 0.87 | CPT1A (0.56) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL1261499 | 0.87 | MAPT (0.61) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL3580222 | 0.86 | MAPT (0.64) | CPT1ACPT2MAPTSMN1; SMN2TP53 | |
| SCHEMBL3582338 | 0.84 | RORC (0.63) | CPT1ACPT2MAPTSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996563-B1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | HOFFMANN LA ROCHE (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-8030308-B2 | Bicyclic sulfonamide derivatives which are L-CPT 1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2011-10-04 | — | — | US | disclosed |
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2011-02-24 | — | — | US | disclosed |
| US-7879845-B2 | Liver carnitine-dependent palmitoyltransferase (L-CPT1) inhibitors such as 4-{[4-(5-Chloro-2-methoxy-benzenesulfonyl)-3,4-dihydro-2H-benzo[1,4]thiazine-6-carbonyl]-amino}-benzoic acid, used for the treatment of non-insulin dependent diabetes; antidiabetic agents | HOFFMANN-LA ROCHE INC. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | ACKERMANN JEAN | 2010-05-27 | — | — | US | disclosed |
| US-7696200-B2 | Bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1996563-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007093507-A1 | HETEROBICYCLIC SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF DIABETES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-08-23 | — | — | WO | disclosed |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046112-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885MAPT 3162/4885 |
| US-20100130484-A1 | NOVEL BICYCLIC SULFONAMIDE DERIVATIVES WHICH ARE L-CPT1 INHIBITORS | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885MAPT 3162/4885 |
| US-20070191603-A1 | Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors | CPT1A, CPT1B, CPT2 | CPT1A 1/4885CPT2 3/4885MAPT 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.